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Abstract:  The dried rhizome of Belamcanda chinensis is an important Chinese traditional medicine used for the 
treatment  of  inflammation  and  many  other  disorders.  Previously,  we  reported  the  hypo-  and  antihyper-glycemic 
effects of the aqueous leaf extract of B. chinensis (BCL) and identified the isoflavones as its principal active fraction. 
In the present study, the α-glucosidase inhibitory effect of BCL and its rough isoflavone preparation (BIF) was tested 
in vitro and in vivo. Thirteen isoflavones were isolated from BCL and their α-glucosidase inhibitory activity was 
screened in vitro. The results showed that BCL (500 and 1000 mg/kg) and BIF (250 and 500 mg/kg) greatly inhibited 
the increase in blood glucose level after 5 g/kg starch loading in normal mice. Six out of the thirteen isoflavones 
(swertisin, 2”-O-rhamnosylswertisin,  genistein,  genistin,  mangiferin  and  daidzin) exhibited  strong  α-glucosidase 
inhibitory activity in vitro. HPLC analysis showed that swertisin was the most abundant isoflavone in BCL accounting 
for 1.24% of BCL, 7.44% of BIF, and 11.24% of the total isoflavone fraction of BCL, respectively. These results 
demonstrate  that BCL  possesses significant α-glucosidase inhibitory activity and swertisin  may  be the principal 
active component of BCL in α-glucosidase inhibition. 
   
Keywords:    Belamcanda  chinensis,  diabetes,  α-glucosidase  inhibitor,  swertisin,  isoflavones,  postprandial 
hyperglycemia 
 
1. Introduction 
Diabetes mellitus is one of the most prevalent diseases seriously threatening the health of humans. 
It is predicted that in 2010, the number of diabetic patients has soared to 285 million, accounting for 
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approximately 6.4% of the world’s adult population [1]. Each year, more than 3.8 million people die from 
diabetes-related causes [2]. The overwhelming prevalence of diabetes not only imposes a huge burden on 
global health care, costing at least 376 billion U.S. dollars or 12% of the total health care expenditures in 
2010 [3], but also makes the searching for agents with antidiabetic activities one of the most urgent and an 
endless issue for pharmacologists all over the world. 
 In diabetes, the postprandial phase is characterized by a rapid and large increase in blood glucose 
levels, which is called postprandial hyperglycaemia or “hyperglycemic spikes”. Recently, a growing body 
of  evidence  suggests  that postprandial hyperglycaemia  is  an  important and independent risk  factor  for 
atherosclerosis and some other diabetic complications with great effects than that of fasting hyperglycemia 
alone  [4-6].  Effective  management  of  postprandial  hyperglycemia  therefore  involves  not  only  the 
maintenance of normal blood glucose levels after meal but also the prevention of many other diabetic 
complications. In this realm, the α-glucosidase inhibitors attract most interest [7-9].  
Alpha-glucosidase is a key enzyme in carbohydrate digestion. It catalyzes the hydrolysis of 1,4-α-
glucosidic  bonds  within  carbohydrates  with  release  of  α-glucose  and  promotes  the  increase  of  blood 
glucose levels after meal. Alpha-glucosidase inhibitors antagonize the activity of α-glucosidase, thereby 
delaying intestinal carbohydrate absorption and slowing the sharp rise in blood sugar levels that diabetic 
patients typically experience after meals [7]. For this reason, α-glucosidase inhibitors, such as acarbose and 
voglibose, are clinically used as oral antihyperglycemic agents [8-9]. However, they often cause severe 
gastrointestinal  side  effects  such  as  flatulence  and  diarrhea.  Therefore,  search  for  new  α-glucosidase 
inhibitors  from  natural  resources  has  become  an  attractive  approach  for  the  treatment  of  postprandial 
hyperglycemia. 
Belamcanda chinensis (L) DC belongs to the family Iridaceae. Its dried rhizome is an important 
Chinese traditional medicine used for the treatment of sore swollen throat, asthma, tonsillitis, and many 
other  symptoms  [10-11].  In  our  previous  studies,  we  demonstrated  the  hypo-  and  antihyper-glycemic 
effects  of  the  aqueous  leaf  extract  of  B.  chinensis  (BCL)  in  normal  and  STZ  (Streptozocin)-induced 
diabetic  rats [12-13].  Oral  administration  of  BCL  significantly  inhibited  the increase  of  blood  glucose 
levels  after  administration  of  various  carbohydrates.  Interestingly,  BCL  was  more  effective  for  the 
carbohydrates with complicated structures such as starch and pulse flour [12], suggesting that BCL likely 
possess glycosidase inhibitory activities. In our subsequent investigations, we identified the isoflavones but 
not  polysaccharides  as  the  principal  active  fraction  of  BCL  in  diabetes  treatment  and  isolated  several 
isoflavones with known antidiabetic activities from this source [12-13], providing more detailed and solid 
evidence for the antidiabetic effects of the aqueous leaf extract of B. chinensis (BCL).  
In the present study, the α-glucosidase inhibitory effects of the aqueous leaf extract of B. chinensis 
(BCL) were investigated in vitro and in vivo. Thirteen major isoflavones isolated from BCL were screened 
for the α-glucosidase inhibitory activity in vitro. Eventually, swertisin was identified as the principal active 
component of BCL in α-glucosidase inhibition. 
 
2. Materials and Methods 
 
2.1. Plant materials 
 
2.1.1 Plant extracts preparation 
 
Belamcanda  chinensis  (L)  DC  leaves  were  harvested  from  Hainan  province,  South  China  and 
authenticated by Dr. Hubiao Chen (Peking University Health Science Center, Beijing, China). A voucher 
specimen (No. H200507) has been deposited in the laboratory of the School of Life Sciences, Beijing 
Institute  of  Technology.  The  aqueous  extract  (BCL)  and  the  crude  isoflavone  preparation  (BIF)  of  B. 
chinensis leaves were prepared as previously reported [12-13].  
 
2.1.2. Isolation and identification of compounds 
 α-glucosidase inhibitors from Belamcanda chinensis  
 
112
The separation procedure and the amount of each isoflavone obtained were shown in Figure 1. 
Briefly, the dried powder of BIF (50 g) was dissolved in 300 mL of methanol, filtered and then methanol 
was evaporated out of the supernatant, which yielded about 41 g of methanol extract. The methanol extract 
was loaded onto a polyamide column (85 cm x 8 cm) and thoroughly eluted in steps with pure water, 40% 
and 95% ethanol. The pure water and 40% ethanol eluates were reloaded onto a separate Sephadex-LH20 
column (21 cm x 2.5 cm) and sequentially eluted with pure water, 30%, 50% and 70% methanol (for the 
pure water eluate) or with 30%, 50%, 70% and 100% methanol (for the 40% ethanol eluate). The 95% 
ethanol eluate was reloaded onto an octadecyl silane (ODS) column (25 cm x 2.0 cm) and sequentially 
eluted with 40%, 55%, 70%, 80% and 100% methanol. All the subeluates obtained from the second cycle 
of column chromatography were individually loaded onto a preparative HPLC column and eluted with 
indicated concentrations of methanol.  
 
 
 
Figure  1.  Isolation  scheme  of  isoflavones  (1-13)  from  the  crude  isoflavone  preparation  (BIF)  of  B. 
chinensis leaf extract (BCL). EtOH, ethanol; MeOH, methanol. 
 
The NMR and MS data were obtained for each compound and compared with those reported in the 
literature.  All  the  compounds  are  known  chemicals  and  identified  as  (1)  swertisin  [14],  (2)  2”-O-
rhamnosylswertisin  [15],  (3)  isovitexin  [16],  (4)  2”-O-rhamnosylisovitexin  [17],  (5)  iridin  [18],  (6) 
tectoridin  [18],  (7)  sophoricoside  [19],  (8)  genistein  [20],  (9)  genistin  [21],  (10)  prunetin  [22],  (11) 
quercitrin  [23],  (12)  mangiferin [24],  and  (13)  daidzin  [25].  The  chemical  structures  of  these  thirteen 
isoflavones isolated from B. chinensis leaf extract are displayed in Figure 2. 
 
 
 
 
 
2.1.3. HPLC and isoflavone content determination 
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0.15 g of B. chinensis leaf extract (BCL) was dissolved in 2 mL of deionized water and filtered 
through a 0.45 µm syringe filter. An aliquot of 5 µl solution was injected for HPLC analysis. An Agilent 
1100 series HPLC system (Agilent Technologies, Santa Clara, CA USA) with an Agilent ODS column 
(250 mm×4.6 mm i.d., 5 µm) was used to acquire HPLC chromatograms. The mobile phase consisted of 
phosphoric acid solution (0.05% (v/v), pH 3.24, A) and acetonitril (B) using a linear gradient program of 
5% B in 0-5 min, 5-15% B in 5-20 min, 15-20% B in 20-30 min, 20-30% B in 35-45 min, 30-100% B in 
45-60 min. The flow rate was 1.0 mL/min. The DAD detector was set at 269 nm. 
The contents of swertisin and 2”-O-rhamnosylswertisin in BIF were determined by comparing their 
peak  areas  in  HPLC  chromatographs  with  that  obtained  from  a  known  weight  of  swertisin  or  2”-O-
rhamnosylswertisin, respectively. Briefly, serial dilutions (0.005, 0.010, 0.015, 0.020 and 0.025 mg/mL) of 
swertisin and 2”-O-rhamnosylswertisin were prepared in 50% methanol. An aliquot of 5 µl dilution was 
injected for HPLC analysis under the same HPLC conditions as described above. The peak areas were 
plotted against the concentration of swertisin or 2”-O-rhamnosylswertisin, and the standard curves were 
obtained. Thereafter, 0.75 g of BIF was dissolved in 25 mL of 50% methanol and filtered through a 0.45 
µm  syringe filter.  An  aliquot  of  5  µl  solution was  injected  for  HPLC analysis under the  same HPLC 
conditions as described above. The corresponding peak areas were obtained and the contents of swertisin or 
2”-O-rhamnosylswertisin were calculated from the standard curves. Six BIF samples were analyzed under 
the same HPLC conditions.  
The percent total isoflavone content in BIF fractions was determined by the absorption at 269 nm 
with 2”-O-rhamnosylswertisin as standard. A precise weight of 21.6 mg of 2”-O-rhamnosylswertisin was 
dissolved in 50% methanol to a final volume of 50 mL. Then, aliquots of 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 
0.40,  0.45,  0.50,  0.55,  0.60  and  0.65  mL  were  taken  and  diluted  to  10  mL  with  50%  methanol.  The 
absorption of each aliquot at 269 nm was measured in a Beckman DU7400 spectrophotometer and plotted 
against  the  corresponding  concentrations  to  obtain  the  standard  curve.  Thereafter,  0.75  g  of  BIF  was 
dissolved in 25 mL of 50% methanol and filtered through a 0.45 µm syringe filter. The absorption at 269 
nm was measured and the total isoflavone content was calculated from the standard curve. Six BIF samples 
were tested. 
 
Figure 2. Chemical structures of thirteen isoflavones isolated from B. chinensis leaf extract (BCL). α-glucosidase inhibitors from Belamcanda chinensis  
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2.2. Animal experiment 
 
Male  Kunming  mice  (20-22  g  each)  were  obtained  from  the  Institute  of  Laboratory  Animal 
Science, Chinese Academy of Medical Sciences, Beijing, China. The study was carried out according to the 
“  Principles  of  Laboratory  Animal  Care”  [World  Health  Organization  (WHO)  Chronicle,  1985]  and 
approved by the Animal Ethics Committee of our university. A standard pellet diet and water were given 
ad libitum. Animals were maintained under a constant 12-h light and dark cycle and an environmental 
temperature of 21-23 °C. 
Animals  were  randomly  divided  into  six  groups  with  six  mice  in  each  group.  Prior  to  the 
experiment,  animals  were  fasted  for  eight  hours  then  treated  with  corresponding  agents  orally.  After 
another 15 min, each mouse was given 5 g/kg of starch (p.o.). The whole blood was collected from the tail 
veins  at  0,  1  and  2  hours  after  starch  administration,  and  the  serum  blood  glucose  concentration  was 
measured by a glucose assay kit (BIOSINO Inc., Beijing, China) according to the vendor’s instruction. 
Negative control group (NC) received distilled water only, whereas positive control group (PC) received 
acarbose (100 mg/kg, p.o.). BCL-L and BCL-H groups were treated with BCL (500 mg/kg and 1000 mg/kg 
respectively, p.o.). BIF-L and BIF-H groups were treated with BIF (250 mg/kg and 500 mg/kg respectively, 
p.o.). 
 
2.3. Assessment of α-glucosidase inhibitory activity in vitro 
 
Inhibition of α-glucosidase activity was performed according to the chromogenic method described 
by Watanabe [26], using 4-nitrophenyl-α-D-glucopyranoside (PNPG, Sigma, USA) as substrate. Briefly, 
BCL  and  Acarbose  were  dissolved  in  distilled  water  while  BIF  and  all  the  isoflavone  samples  were 
dissolved in dimethyl  sulfoxide (DMSO, Sigma, USA) to a final concentration of 4 mg/mL.  Yeast α-
glucosidase (10 U/mL) and PNPG (10 mg/mL) were prepared in 50 mM potassium phosphate buffer (pH 
6.8). Fifty µL of enzyme solution and 5, 10 or 20 µL of test materials were mixed in wells of a microplate. 
After incubation at room temperature for 15 min, PNPG solution was added to a final volume of 200 µL 
and incubated for an additional 15 min at room temperature. The absorbance of 405 nm was measured in a 
microplate reader (BIO-RAD, CA) after stopping the reaction by addition of 600 µL of 1M Na2CO3. The 
corresponding solvents (distilled water and DMSO) were used as blank and Acarbose was used as positive 
control. The α-glucosidase inhibitory activity was calculated as follows:  
α-glucosidase inhibitory activity (%) = [Ablank − (Asample − Abackground)] / Ablank × 100  
Where Ablank, Asample, Abackground are defined as the absorbance of 100% enzyme activity (only the solvent 
with the enzyme), test sample with the enzyme and test sample without the enzyme, respectively. The IC50 
values of compounds were calculated by the linear regression analysis.  
 
2.4. Kinetics of enzyme inhibition 
 
Inhibition assays were performed according to the above reaction conditions with inhibitors of 
various concentrations. The type of inhibition for the inhibitors were determined by double-reciprocal plot 
and its replot of slope versus the reciprocal of the substrate concentration. 
 
2.5. Data analysis 
 
The values were expressed as mean ± SD. Statistical significance was determined by One-way 
ANOVA followed by post-hoc Tukey test using SPSS 11.0 software. A value of p <0.05 was considered 
statistically significant. 
 
3.  Results and Discussion   Wu  et.al., Rec. Nat. Prod. (2012) 6:2 110-120 
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3.1 The Inhibitory effects of BCL and BIF on postprandial hyperglycemia and α-glycosidase activity 
As shown in Figure 3, oral treatment with BCL (500 and 1000 mg/kg) (Figure 3A) or its crude 
isoflavone preparation (BIF) (250 and 500 mg/kg) (Figure 3B) largely inhibited the increase of blood 
glucose levels in normal mice at 1 h after starch intake. The inhibitory effect of BCL and BIF on 
postprandial hyperglycemia was dose-dependent. At the doses used in this experiment, BCL and BIF were 
comparable to 100 mg/kg of Acarbose (Figure 3A and B).  
 
Figure 3. Effect of B. chinensis leaf extract (BCL) (A) and its crude isoflavone preparation (BIF) (B) on 
postprandial hyperglycaemia of normal mice induced by starch intake. NC, negative control treated with 
distilled water; PC, positive control treated with Acarbose (100 mg/kg, p.o.); BCL-L and –H were treated 
with BCL (500 and 1000 mg/kg respectively, p.o.); BIF-L and –H were treated with BIF (250 and 500 
mg/kg respectively, p.o.). 
 
 
Figure 4. Inhibition of yeast α-glucosidase by B. chinensis leaf extract (BCL) and its crude isoflavone 
preparation  (BIF)  in  vitro.  Each  result  is  expressed  as  the  mean  ±  SD  of  three  separate  experiments. 
Acarbose was used as positive control. 
The robust effects of BCL and BIF on postprandial hyperglycemia suggested that the aqueous 
extract  of  B.  chinensis  leaves  has  strong  α-glycosidase  inhibitory  activity,  and  this  hypothesis  was 
confirmed by the in vitro α-glycosidase inhibition assay. BCL and BIF dose-dependently inhibited the 
activity of yeast α-glucosidase with IC50 values of about 800 µg/mL and 500 µg/mL, respectively, which 
were lower than that of acarbose (217 µg/mL) (Figure 4). The IC50 values of BCL and BIF was consistent 
with the results obtained from animal experiments, in which 500 mg/kg of BCL and 250 mg/kg of BIF 
displayed comparable inhibitory effects with 100 mg/kg of acarbose on postprandial hyperglycemia (Figure 
3).  
 
 
3.2 In vitro α-glucosidase inhibitory activity screening of isoflavones (1-13) isolated from BCL α-glucosidase inhibitors from Belamcanda chinensis  
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To identify the active components of BCL in α-glucosidase inhibition, thirteen isoflavones were 
isolated  from  the  crude  isoflavone  preparation  (BIF)  of  BCL.  The  inhibitory  effects  of  these  thirteen 
isoflavones on α-glucosidase activity were assayed in vitro. As shown in Figure 5, six isoflavones i.e. 
swertisin (1), 2”-O-rhamnosylswertisin (2), genistein (8), genistin (9), mangiferin (12) and daidzin (13) 
exhibited strong inhibitory effect on α-glucosidase activity. The IC50 values of these isoflavones were listed 
in Table 1. All the compounds except 2”-O-rhamnosylswertisin have already been demonstrated to be 
strong α-glucosidase inhibitors in previous reports [26-28], which confirms our findings.  
 
 
Figure 5. Inhibition of yeast α-glucosidase by isoflavones isolated from B. chinensis leaf extract in vitro. 
Each result is expressed as the mean ± SD of three distinct experiments. Acarbose was used as positive 
control.  (1)  swertisin;  (2)  2”-O-rhamnosylswertisin;  (8)  genistein;  (9)  genistin;  (12)  mangiferin;  (13) 
daidzin. 
Figure  6  displayed  the  double-reciprocal  plots  of  α-glucosidase  kinetics  with  genistein,  genistin, 
mangiferin  and  daidzin.  Non-competitive  inhibition  was  partially  observed  when  genistein,  genistin, 
mangiferin,  and  substrate  were  added  simultaneously,  showing  Ki  values  of  32.4,  254.7  and  138.2 
nmol/mL  respectively.  The  double-reciprocal  plots  of  α-glucosidase  kinetics  with  daidzin  showed  a 
complex inhibition pattern, suggesting that daidzin may inhibit α-glucosidase in both competitive and non-
competitive modes.  
 According to Choi et al. [26], the isoflavone glycosides exhibited a relatively poor inhibitory activity on 
α-glucosidase as compared with the corresponding isoflavone. Figure 5 and Table 1 showed that the α-
glucosidase inhibitory effect of 2”-O-rhamnosylswertisin and genistin was significantly weaker than their 
less-glycosylated counterpart swertisin and genistein, which was in good accordance with Choi et al. These 
results also suggest that the aglycone moieties but not the glycone moieties of these isoflavones bind and 
inhibit α-glucosidase. However, experimental results are still needed to confirm this hypothesis. 
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Figure 6. Double-reciprocal plots of the inhibition kinetics of yeast α-glucosidase by genistein, genistin, 
mangiferin and daidzin. α-Glucosidase (20 µl, 2 U/ml) was pre-incubated with each inhibitor for 15 min at 
room temperature before 4-nitrophenyl-α-D-glucopyranoside (PNPG) was added to initiate the reaction.   
 
 
 
 
 
Table 1. α-glucosidase inhibitory effects of isoflavones (1-13) on α-glucosidase 
Compounds  IC50 (µg/mL) 
swertisin (1)  119 
2’’-O-rhamnosylswertisin (2)  333 
isovitexin (3)  --- 
2’’-O-rhamnosylisovitexin (4)  --- 
iridin (5)  --- 
tectoridin (6)  --- 
sophoricoside (7)  --- 
genistein (8)  74 
genistin (9)  83 
prunetin (10)  --- 
quercitrin (11)  --- 
mangiferin (12)  112 
daidzin (13)  97 
acarbose  217 α-glucosidase inhibitors from Belamcanda chinensis  
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IC50 represents the concentration of a compound required for 50% inhibition of α-glucosidase in vitro. Acarbose was 
used as a positive control. “---” denotes no inhibitory effect. 
3.3 Swertisin may be the principal active component of BCL in α-glucosidase inhibition 
 
Swertisin (1) and  2”-O-rhamnosylswertisin (2) were the most abundant compounds among those 
isolated from BCL. The amounts of swertisin and 2”-O-rhamnosylswertisin obtained from 50 g BIF were 
2500 mg and 900 mg, respectively, much higher than the other isoflavone components (Figure 1 and Figure 
6A). Quantitative analysis showed that swertisin accounted for 1.24% of BCL, 7.44% of BIF, and 11.24% 
of the total isoflavone fraction of BCL, whereas 2”-O-rhamnosylswertisin was approximately one-third of 
swertisin (Figure 6B). Based on its strong inhibitory effect on α-glucosidase activity and most abundance in 
BCL, swertisin might be the principal active component of BCL responsible for α-glucosidase inhibition. 
 
Figure  7.  Swertisin  is  the  most  abundant  isoflavone  in  B.  chinensis  leaf  extract  (BCL).  (A)  HPLC 
chromatogram of BCL. HPLC analysis was carried out on an Agilent 1100 series HPLC system with an 
Agilent ODS column (250 mm×4.6 mm i.d., 5 µm). A DAD230 diode array detector was used to monitor 
continuously  at  269  nm.  (B)  The  percent  contents  of  BCL,  crude  isoflavone  preparation  (BIF),  total 
isoflavone fraction, swertisin and 2”-O-rhamnosylswertisin in the dried leaves of B. chinensis. 
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